

CURRICULUM VITAE

DAVID HARRY MOORE, MD

Demographic Data

Born: Lake Charles, Louisiana
September 19, 1955

Raised: Frankfort, Indiana

Married: Mary Kristine Beckwith, MD
May 3, 1986

Children: Harry William Moore
April 4, 1993

Aaron Lester Moore
June 23, 1995

Address: Office
Gynecologic Oncology of Indiana
5255 East Stop 11 Road, Suite 310
Indianapolis, IN 46237
(317) 851-2555
(317) 851-2566 FAX
David.Moore@ssfhs.org

Education

Undergraduate
Wabash College (BA - Biology)
Crawfordsville, Indiana
1974-1978

Medical School
Indiana University School of Medicine (MD - Medicine)
Indianapolis, Indiana
1978-1982

Residency
Obstetrics and Gynecology
Indiana University School of Medicine
Indianapolis, Indiana
1982-1986

Fellowship
Gynecologic Oncology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
1986-1988

Academic Appointments

Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
The University of North Carolina at Chapel Hill, NC
Assistant Professor 1988-1993

Department of Obstetrics and Gynecology
Section of Gynecologic Oncology
Indiana University School of Medicine
Indianapolis, Indiana
Associate Professor 1993-1999
Chief of Gynecologic Oncology 1998-2006
Professor 1999-2004
Mary Fendrich Hulman Professor in Gynecologic Oncology 2004-2006

College of Pharmacy and Health Sciences
Physician Assistant Program
Butler University
Indianapolis, Indiana
Adjunct Professor 2000-2004

Board Certification

American Board of Obstetrics and Gynecology:
Diplomate: December 8, 1989
Fellow: September 30, 1990
Annual Board Recertification Passed 2009

Subspecialty of Gynecologic Oncology:
Written Examination Passed June 26, 1989
Oral Examination Passed December 4, 1990
Annual Board Recertification Passed 2009

Licensure

Indiana #01031933
North Carolina #30074 (inactive)

Current Hospital Appointments

St. Francis Hospitals and Health Systems
Community Hospital North
Community Hospital East
Community Hospital South
Clarian North Hospital
Clarian West Hospital
Clarian Hospitals:
Indiana University Hospital
Methodist Hospital of Indiana

Honors

College
Presidential Scholar 1974-1978

Phi Beta Kappa 1977
Sigma Xi 1978
Mills Prize in the Bible 1978
Mckintosh Fellow in Biology 1978
Summa Cum Laude Graduate 1978

Medical

Alpha Omega Alpha 1982
Rheinhardt Award in Obstetrics and Gynecology 1982
Graduated with Highest Distinction 1982

Residency

First Place Award for Resident Research Project 1985
Administrative Chief Resident 1985-1986

Faculty

Department of Ob/Gyn Junior Faculty Teaching Award
The University of North Carolina at Chapel Hill, NC 1993

Munsick-Ragan Outstanding Ob/Gyn Faculty Teaching Award
Indiana University School of Medicine 1996

Department of Ob/Gyn Medical Student 4.0 Club Award
Indiana University School of Medicine 2001

America's Top Doctors, Castle Connolly Guide 2001, 2004, 2007

2004 "Healing Spirit" Award from The Wellness Community

AcademicKeys Who's Who in Medical Sciences Education 2005
<http://medicine.academickeys.com/whoswho.php>

Department of Ob/Gyn Medical Student 4.0 Club Award
Indiana University School of Medicine 2005

Best Doctors in America 2005-2006 database

Societies/Memberships

Professional

Indiana State Medical Association
Indianapolis Medical Society
American College of Obstetricians and Gynecologists (Fellow)
American College of Surgeons (Fellow)
Society of Gynecologic Oncologists
Gynecologic Oncology Group
International Society of Gynecologic Oncology
American Society of Clinical Oncology
Hoosier Oncology Group
Robert A. Ross Obstetrical and Gynecological Society
Phi Rho Sigma Medical Society
Minimally Invasive Robotic Association (MIRA)

Social

Second Presbyterian Church
Byron K. Trippet Society of Wabash College
Sigma Chi Fraternity
Indiana University Alumni Association
Indiana University School of Medicine Dean's Council
Alpha Association of Phi Beta Kappa
New York Road Runners Club
American Medical Athletic Association
United States Golf Association
Old Oakland Golf Club
Wolf Run Golf Club
Indiana Bicycle Coalition
Sierra Club
American Numismatic Association

Ongoing Research

1. "A phase II study of radiation therapy and weekly cisplatin chemotherapy in locally-advanced squamous cell carcinoma of the vulva." Principal Investigator: GOG protocol 205.

Publications

Chapters

Moore DH, Walton LA. Gyn cancer: guidelines for the followup of the cancer patient (a handbook for physicians). North Carolina Division of the American Cancer Society. 1st Ed. 1987:6-9. 2nd Ed. 1992:8-12.

Moore DH. Colocutaneous fistula. In: Cefalo RC, ed. Clinical decisions in obstetrics and gynecology. Rockville, Maryland: Aspen Publishers, 1990:277-8.

Moore DH. Prophylactic oophorectomy: can ovarian cancer be prevented? In: Cefalo RC, ed. Clinical decisions in obstetrics and gynecology. Rockville, Maryland: Aspen Publishers, 1990:321-3.

Moore DH. Primary surgical management of early epithelial ovarian carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill, 1993:219-39.

Moore DH. Anatomy and pathology of the cervix. In: Moore T, Reiter RC, Rebar RW, Baker VV, eds. Gynecology and obstetrics: an integrated approach. New York: Churchill Livingstone, 1993:689-98.

Halme JK, Moore DH. Laparoscopic management of persistent ovarian masses. In: Hulka JF, Reich H, eds. Textbook of laparoscopy. 2nd Ed. Philadelphia: WB Saunders Company, 1993:253-8

Moore DH. Anatomy, natural history, and patterns of spread of invasive cervical cancer. In: Rubin SC, Hoskins WJ, eds. Cervical cancer and preinvasive neoplasia. New York: Lippincott-Raven Publishers, 1996:161-70.

Moore DH. Familial ovarian cancer; Ovarian cancer, epithelial tumor with multiple previous therapies; Locally advanced cervical cancer in a woman who is HIV-positive.

In: Markman M, Belinson JL. Expert consultations in gynecological cancers. New York, Marcel Dekker, Inc., 1997:33-4;208-9;424-5.

Moore DH. Advances in the treatment of cervical cancer. In: Ozols RF, ed. Diagnostic and therapeutic advances in gynecologic oncology. Boston: Kluwer Academic Publishers, 1998:149-76.

Moore DH. Gynecologic cancers. In: Hunter CP, Johnson KA, Muss HB, eds. Cancer in the elderly. New York: Marcel Dekker, Inc., 2000:267-90.

Moore DH. Contemporary management of squamous cell carcinoma of the cervix. In: Current problems in obstetrics, gynecology and fertility. St. Louis: Mosby, Inc., 2000:23:161-190

Moore DH. Primary surgical management of early epithelial ovarian carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian cancer. 2nd Ed. New York: McGraw-Hill, 2001:201-218.

Cardenes HR, Moore DH, Long HJ, Randall ME. Chapter 9: Treatment of recurrent vaginal, vulvar and cervical cancer. In: Gershenson DM, McGuire WP, Gore M, Quinn MA, Thomas GM, eds. Gynecologic cancer: controversies in management. Philadelphia: Elsevier Science, 2004:119-132.

Moore DH, Koh WJ, McGuire WP, Wilkinson EJ. Chapter 20: Vulva. In: Hoskins WJ, Perez CA, Young RC Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 4th Ed. New York: Lippincott Williams & Wilkins, 2005:665-705.

Moore DH. Chapter 15: Cervical, endometrial and vulvar cancer. In: Muss HB, Hunter CP, Johnson KA, eds. Treatment and management of cancer in the elderly. New York: Taylor & Francis Group, 2006:303-332.

Spitzer M, Moore DH. Cervical neoplasia. In: Oncology *Precis*. 3rd Ed. Washington, DC: The American College of Obstetricians and Gynecologists, 2008:51-73.

Moore DH, Koh WJ, McGuire WP, Wilkinson EJ. Chapter 20: Vulva. In: Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 5th Ed. Philadelphia: Lippincott Williams & Wilkins, 2009:555-590.

Manuscripts

Moore DH, Woosley JT, Reddick RL, Walton LA, Siegal GP. Adenosquamous carcinoma of the Fallopian tube. *Am J Obstet Gynecol* 1987;157:903-5*

Moore DH, Jarrett JC, Bendick PJ. Exercise-induced changes in uterine artery blood flow, as measured by Doppler ultrasound, in pregnant subjects. *Am J Perinatol* 1988;5:94-7*

Fowler WC, Maddock MB, Moore DH, Haskill S. Significance of multiparameter flow cytometric analysis of ovarian cancer. *Am J Obstet Gynecol* 1988;158:838-43*

Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. *Int J Radiation Oncology Biol Phys* 1989;17:21-7*

Moore DH, Fowler WC, Walton LA, Droegemueller W. Morbidity of lymph node sampling in cancers of the uterine corpus and cervix. *Obstet Gynecol* 1989;74:180-4*

Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ cell tumors: a trial of the Gynecologic Oncology Group. *Ann Intern Med* 1989;111:22-7*

Moore DH, Fowler WC, Crumpler LS. 5-Fluorouracil neurotoxicity. *Gynecol Oncol* 1990;36:152-4*

Moore DH. The role of radiation therapy in ovarian cancer. *Current Opinion in Obstetrics and Gynecology* 1990;2:64-8

Moore DH, Fowler WC, Olafsson K, Haskill S. Class I histocompatibility antigen expression: a prognostic factor for aneuploid ovarian cancers. *Gynecol Oncol* 1990;38:458-61*

Moore DH, Fowler WC, Currie JL, Walton LA. Squamous cell carcinoma of the vulva in pregnancy. *Gynecol Oncol* 1991;41:74-7*

Moore DH, Fowler WC, Jones CP, Crumpler LS. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. *Am J Obstet Gynecol* 1991;165:573-6*

Moore DH, Fowler WC, Santrach PJ. Malignant endometrioid cystadenofibroma of the ovary. *Arch Gynecol Obstet* 1991;249:153-6*

Moore DH, Dotters DJ, Fowler WC. Computed tomography: does it really improve the treatment of cervical carcinoma? *Am J Obstet Gynecol* 1992;167:768-71*

Moore DH, Rouse MB, Massenburg GS, Zeman EM. Description of a spheroid model for the study of chemotherapy and radiation effects on hypoxic tumor cell populations. *Gynecol Oncol* 1992;47:44-7*

Moore DH. Surgical staging of endometrial adenocarcinoma. *Clin Consult Obstet Gynecol* 1993;5:100-7

Moore DH. The impact of I. C. Rubin on Obstetrics and Gynecology. *Obstet Gynecol Surv* 1993;48:589-90

Moore DH. New therapies in the treatment of ovarian cancer. *The Female Patient* 1993;18:29-32.

Moore DH, Valea FA, Crumpler LS, Fowler WC. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma. *Gynecol Oncol* 1993;51:109-12*

Schust DJ, Moore DH, Baird DB, Novotny DB. Primary adenocarcinoma of the gallbladder presenting as primary gynecologic malignancy: a report of two cases. *Obstet Gynecol* 1994;83:831-4S*

Ghosh K, Moore DH, Sutton GP. Epithelial ovarian cancer complicating renal transplantation. *Am J Obstet Gynecol* 1994;171:276-7*

Moore DH, Ghosh K, Sutton GP. Spontaneous occurrence of gangrene due to Clostridium septicum in a patient with advanced endometrial carcinoma. Infect Dis Obstet Gynecol 1994;2:34-7*

Moore DH. Ovarian cancer in the elderly patient. Oncology 1994;8:21-24*

Van Le L, Fakhry S, Walton LA, Moore DH, Fowler WC, Rutledge R. Use of the APACHE II scoring system to determine mortality of gynecologic oncology patients in the intensive care unit. Obstet Gynecol 1995;85:53-6*

Feeney DD, Moore DH, Look KY, Stehman FB, Sutton GP. The fate of the ovaries after radical hysterectomy and ovarian transposition. Gynecol Oncol 1995;56:3-7*

Moore DH. Evaluation and staging of cervical carcinoma. Clin Consult Obstet Gynecol 1995;7:111-7

Look KY, Stehman FB, Moore DH, Sutton GP. Intraperitoneal 5-fluorouracil for pseudomyxoma peritonei. Int J Gynecol Oncol 1995;5:361-5*

Valea FA, Haskill S, Moore DH, Fowler WC. Immunohistochemical analysis of α_1 - integrins in cervical cancer. Am J Obstet Gynecol 1995;173:808-13.

Moore DH, Valea F, Walton LA, Soper J, Clarke-Pearson, D, Fowler, WC. A phase I study of intraperitoneal alpha_{2b} interferon and intravenous cisplatin plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1995;59:267-72*

Geisler JP, Look KY, Moore DH, Sutton GP. Pelvic exenteration for malignant melanomas of the vagina or urethra with over 3 mm of invasion. Gynecol Oncol 1995;59:338-41*

McGuire WP, Blessing JA, Moore D, Lentz SS, Photopoulos G. Taxol has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996;14:792-5*

Moore DH, Valea FA, Van Le L. Newer treatments in gynecologic cancer. ACOG Update 1996;21:1-10

Asbury R, Blessing JA, Moore D. A phase II trial of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study. Am J Clin Oncol 1996;19:400-2*

Sutton GP, Blessing JA, DeMars LR, Moore DH, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996;63:25-7*

Moore DH, Stehman FB. What is the appropriate management of low-stage cervical cancer (FIGO stages I-IIA)? Monogr Natl Cancer Inst 1996;21:43-6*

Moore DH, Allison B, Look KY, Sutton GP, Bigsby RM. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol 1997;65:78-82*

Gilbey S, Moore DH, Look KY, Sutton GP. Vulvar keratoacanthoma. Obstet Gynecol 1997;89:848-50*

Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. *Anticancer Res* 1997;17:2353-6*

Moore DH, Falender MJ. Inflammatory pseudotumor of the pelvis. *Journal of Pelvic Surgery* 1997;3:214-7*

Xu Y, Moore DH, Broshears JR, Liu L, Wilson TM, Kelley MR. The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. *Anticancer Res* 1997;17:3713-9*

Moore DH. Surgical management of endometrial hyperplasia. *J Gynecol Techniques* 1997;3:177-82

Schilder JM, Hurteau JA, Look KY, Moore DH, Raff G, Stehman FB, Sutton GP. A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery. *Gynecol Oncol* 1997;67:235-40*

Markman M, Blessing JA, Moore DH, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant ovarian cancer: A Gynecologic Oncology Group phase II trial. *Gynecol Oncol* 1998;69:226-9*

Moore DH, Michael H, Furlin JJ, Von Stein A. Adenoid basal cell carcinoma of the vagina. *Int J Gynecol Oncol* 1998;8:261-3*

Moore DH, Thomas GM, Montana GS, Bundy BN, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: A phase II study of the Gynecologic Oncology Group. *Int J Radiat Oncol Biol Phys* 1998;42:1317-23*

Moore DH, Wilson DK, Hurteau JA, Look KY, Stehman FB, Sutton GP. Gynecologic cancers metastatic to the breast. *J Am Coll Surg* 1998;187:178-81*

Burger RA, DiSaia PJ, Roberts JA, O'Rourke M, Gershenson DM, Homesley HD, Lichtman SM, Barnes W, Moore DH, Monk BJ. Phase II trial of vinorelbine in advanced epithelial ovarian cancer. *Gynecol Oncol* 1999;72:148-53*

Hurteau JA, Allison B, Sutton GP, Moore DH, Look KY, Hurd W, Bigsby RM. Transforming growth factor- β differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21^{WAF1}. *Cancer* 1999;85:1810-5*

Berek JS, Markman M, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D. Intraperitoneal alpha-interferon in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. *Gynecol Oncol* 1999;75:10-14*

Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K. FIGO stage IIIc endometrial carcinoma with metastases confined to pelvic lymph nodes: Analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. *Gynecol Oncol* 1999;75:211-4*

Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Evaluation of dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. *Gynecol Oncol* 1999;75:473-5*

Moore DH, Michael H, Tritt R, Kelley MR. Alterations in the expression of the DNA repair/redox enzyme APE/REF-1 in epithelial ovarian cancers. *Clin Cancer Res* 2000;6:602-9*

Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, Averette HE. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 2000;48:1007-13*

Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP. Phase II study of paclitaxel and Valspodar (PSC 833) in refractory ovarian carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2001;19:2975-2982*

Moore DH. The role of radical hysterectomy and neoadjuvant chemotherapy in carcinoma of the cervix. *Curr Oncol Rep* 2002;4:145-51

Moore DH. Controversies in the management of gynecologic malignancies. *ASCO News* 2002;14:23-4

Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2003;88:130-5*

Moore DH. Neoadjuvant chemotherapy for cervical cancer. *Expert Opin Pharmacother* 2003;4:859-67*

Moore DH. Treatment of stage IB2 (bulky) cervical carcinoma. *Cancer Treat Rev* 2003;29:401-6*

Freitas S, Moore DH, Michael H, Kelley MR. Studies of APE/REF-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. *Clin Cancer Res* 2003;9:4689-94*

Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE. Limited access trial using amifostine for protection against cisplatin- and 3-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. *J Clin Oncol* 2003;21:4207-13*

Balega J, Michael H, Hurteau J, Moore DH, Santiesteban J, Sutton GP, Look KY. The risk of nodal metastasis in early adenocarcinoma of the uterine cervix. *Int J Gynecol Cancer* 2004;14:104-9*

Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. *Gynecol Oncol* 2004;94:368-74*

Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. Corrigendum to "an assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study." *Gynecol Oncol* 2004;95:778*

Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group trial. *J Clin Oncol* 2004;22:3113-9*

Moore DH. Optimal therapy for relapsed carcinoma of the cervix after primary chemoradiation (reply). *J Clin Oncol* 2004;22:5022*

Morris M, Blessing JA, Monk BJ, McGehee R, Moore DH. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *J Clin Oncol* 2004;22:3340-44*

Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM. Secondary surgical cytoreduction for advanced ovarian carcinoma. *N Engl J Med* 2004;351:2489-97*

Moore DH. Combined chemotherapy and radiation therapy for cervical cancer. *JNCCN* 2004;2:631-5*

Fakiris AJ, Moore DH, Reddy SR, Look KY, Yiannoutsos CT, Randall ME, Cardenes HR. Intraperitoneal radioactive phosphorus (³²P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study. *Gynecol Oncol* 2005;96:818-23*

Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA, Moore DH, Monk BJ, O'Connor DM. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2005;23:8289-95*

Moore DH. Clinical expert series: cervical cancer. *Obstet Gynecol* 2006;107:1152-61*

Moore DH. Chemotherapy for recurrent cervical cancer. *Curr Opin Oncol* 2006;18:516-9

McQuellon RP, Thaler HT, Cella D, Moore DH. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2006;101:296-304*

Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA 125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. *Int J Gynecol Cancer* 2006;16:496-500*

Waggoner SE, Darcy KM, Fuhrman B, Parham G, Lucci J, Monk BJ, Moore DH. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. *Gynecol Oncol* 2006;103:853-8*

Garcia AA, Blessing JA, Darcy KM, Lenz HJ, Zhang W, Hannigan E, Moore DH. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynecologic Oncology Group study. *Gynecol Oncol* 2007;104:572-9*

Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical

cancer. JNCCN 2008;6:53-57*

Moore DH. Surgical staging and cervical cancer: After 30 years, have we reached a conclusion? Cancer 2008;112:1874-6*

Plaxe SC, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. Influence of race on tolerance of platinum based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of three Gynecologic Oncology Group studies. Am J Obstet Gynecol 2008;199:539.e1-6*

Moore DH. Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one? Gynecol Oncol 2009;113:379-83*

Moore DH, Tian C, Monk BJ, Long HJ, Omura G, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:44-9*

Wagner JD, Evdokimow DZ, Weisberger E, Moore D, Chuang TY, Wenck S, Coleman JJ. Sentinel node biopsy for high-risk non-melanoma cutaneous malignancy. Submitted for publication (Arch Dermatol)*

Moore DH, Brady MF, Bonomi P, Stehman FB, DiSaia PJ, Lincoln ST, Walton LA, Major FJ. Multivariate analysis of patients with advanced squamous cell carcinoma of the cervix treated with cisplatin chemotherapy: a Gynecologic Oncology Group study. Manuscript submitted to GOG Publications Committee

Watkins JM, Cardenes HR, Randall ME, Gaffney DK, Moore DH, Watson GA, Lee RJ. FIGO stage I neuroendocrine small-cell carcinoma of the cervix: retrospective analysis of outcome and patterns of failure. Manuscript in progress

*Peer-Reviewed Journal

Abstracts

Fowler W, Haskill S, Olafsson K, Moore D. Significance of class I gene expression in ovarian cancer. Gynecol Oncol 1989;32:107

Montana GS, Moore DH, Marshall R, Thomas GM. A phase II evaluation of preoperative chemoradiation for advanced vulvar cancer. 3rd Meeting of Int Gynecol Oncol Cancer Society, 9/22-26/91, Cairns, Australia

Valea FA, Haskill S, Moore DH, Fowler WC. Changes in integrin expression in cervical cancer. Gynecol Oncol 1992;45:85

Moore D, Zeman E, Massenburg G, Rouse B, Raleigh J. Use of a spheroid model to study chemotherapy and radiation effects on proliferating and hypoxic tumor cell populations. Gynecol Oncol 1992;45:85

Moore D, Varia M, Fowler W, Walton L, Valea F, Van Le L. Hexamethylmelamine chemotherapy and intraperitoneal radioactive chromic phosphate for minimal residual epithelial ovarian cancer following second-look surgery. Gynecol Oncol 1992;45:101

Moore D, Valea F, Van Le L, Crumpler L, Fowler W. Carboplatin versus carboplatin plus ifosfamide chemotherapy of recurrent/persistent epithelial ovarian cancer. Proc ASCO 1993;12:267

Van Le L, Walton L, Moore D, Fowler WC, Fakhry S, Rutledge R. Correlation of APACHE II scores with mortality of critically ill gynecologic oncology patients. Gynecol Oncol 1993;49:125

Shea T, Graham M, Steagall A, Bernard S, Wiley J, Moore D, Gonzales P, Johnston C, Brecher M, Bentley S, Van Le L, Fowler W. Multiple cycles of high dose taxol plus carboplatin with G-CSF (Filgrastim) and peripheral blood progenitor cell support. Proc ASCO 1994;13:150

Moore D, Varia M, Van Le L, Walton L, Fowler W. Radiation plus chemotherapy for recurrent cervical carcinoma. Gynecol Oncol 1994;52:129

Moore D, Varia M, Van Le L, Walton L, Fowler W. Chemoradiation of cervical carcinoma: 10-year experience at a single institution. Gynecol Oncol 1994;52:129

Van Le L, O'Meara AT, Moore DH, DeMars LR, Walton LA, Dotters DJ, Fowler WC. Adjuvant chemotherapy for advanced uterine sarcomas. Gynecol Oncol 1994;52:132

Look KY, Moore DH, Stehman FB, Sutton GP. Phase I trial of carboplatin with 3-hour paclitaxel in patients with peritoneal carcinomatosis. Gynecol Oncol 1995;56:111

Moore DH, Bigsby RM, Allison B. Collagenase expression in ovarian cancer cell lines. J Soc Gynecol Invest 1995;2:233

Look KY, Singhal R, Moore DH, Sutton GP, Weber G. Increased phosphatidylinositol (PI) 4-kinase and PI 4-phosphate (PIP) 5-kinase activities in extracts of malignant ovarian epithelium. Proc ASCO 1995;14:282

Malfetano J, Teng N, Moore D, Barter J, Lopez A, Schink J, Cole A, Rasmussen H. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary: a dose-finding study. Proc ASCO 1996;15:283

Hurteau JA, Devaraju GR, Allison BM, Sutton GP, Look KY, Moore DH, Stehman FB, Bigsby RM. Identification of two differentially expressed cDNA's in metastatic epithelial ovarian cancer cells. J Soc Gynecol Invest (Suppl) 1997;4:119

Moore DH, Xu Y, Broshears J, Kelley MR. The apurinic endonuclease (APE/REF-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. J Soc Gynecol Invest (Suppl) 1997;4:118

Schilder JM, Hurteau JA, Look KY, Raff G, Moore DH, Stehman FB, Sutton GP. A randomized, prospective, unblinded comparison of standard versus early postoperative feeding in patients undergoing major abdominal surgery on a gynecologic oncology service. Gynecol Oncol 1997;64:289

Burger R, DiSaia P, Monk B, Roberts J, O'Rourke M, Homesley H, Gershenson D, Barnes W, Lichtman S, Moore D. Phase II trial of navelbine in advanced epithelial ovarian cancer. Gynecol Oncol 1997;64:299-300

Hurteau JA, Allison B, Sutton GP, Moore D, Look K, Stehman F, Bigsby R. The role of cytokines and cyclin dependent kinase inhibitors in the proliferation of primary human epithelial ovarian cancer cells from different tumor sites. *Gynecol Oncol* 1997;64:335

Moore DH, Wilson DK, Hurteau JA, Look KY, Stehman FB, Sutton GP. Gynecologic cancers metastatic to the breast. *Gynecol Oncol* 1997;64:364

Hurteau JA, Allison BM, Sutton GP, Moore DH, Look KY, Stehman FB, Bigsby RM. TGF- β differentially inhibits epithelial ovarian cancer cells from metastatic sites without upregulation of WAF1. *Proc AACR* 1997;

Malfetano J, Teng N, Barter J, Lopez A, Moore D, Boasberg P, Schink J, Drumheller A, Rasmussen H. Marimastat in patients with advanced cancer of the ovary--a dose-finding study. *Proc ASCO* 1997;16:373

Hurteau JA, Devaraju GR, Allison BM, Sutton GP, Look KY, Moore DH, Stehman FB, Bigsby RM. Differentially expressed cDNAs in metastatic epithelial ovarian cancer cells. *Proc AACR* 1997;38:105

Moore DH, Blessing JA, Dunton C, Buller RE, Reid G. Evaluation of dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. *Proc ASCO* 1998;17:368

Berek JS, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D. Intraperitoneal alpha-interferon in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. *Proc ASCO* 1998;17:358

Hurteau JA, Schwartz CL, Look KY, Moore DH, Stehman FB, Sutton GP. Neobladder formation following pelvic exenterations: Preference of conduits and complications between urological and gynecological surgeons. *Gynecol Oncol* 1999;72:478

Montana GS, Thomas GM, Moore DH, Saxer A, Mangan C, Lentz SM, Averette HE. Preoperative chemo-radiation for carcinoma of the vulva with unresectable lymph nodes: A Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 1999;45 (Suppl 3):208

Hurteau JA, Allison BH, Wang Q, Goebel MG, Hellman DK, Moore DH, Look KY, Sutton GP, Stehman FB, Bigsby RM, Harrington MA. Expression and subcellular localization of the cyclin dependent kinase inhibitor p27^{Kip1} in epithelial ovarian cancer. *J Soc Gynecol Invest* 2000;7:64

Moore DH, Michael H, Tritt R, Parsons SH, Kelley MR. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. *J Soc Gynecol Invest* 2000;7:69

Thaler HT, McQuellon RM, Moore DH, Cella DF. Longitudinal assessment of quality of life in advanced cervical cancer. *Proc Int Soc QOL Research Online* 2000 (Abstract #1756)

Balega J, Michael H, Hurteau JA, Moore DH, Sutton GP, Look KY. The risk of nodal metastasis in early adenocarcinoma of the uterine cervix. *Gynecol Oncol* 2000;76:235

Raff GJ, Michael H, Moore DH, Look KY, Sutton GP, Stehman FB, Hurteau JA. The accuracy of frozen section in ovarian tumors of low malignant potential. *Gynecol Oncol* 2000;76:282

Moore DH, McQuellon RP, Blessing JA, Thaler H, Benda J, Miller DS, Olt G, King S, Boggess J, Rocereto TF. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Proc ASCO* 2001;20:201a

Dunlop J, Schilder JM, Dearnley D, Hurteau JA, Moore DH, Look KY. Comparison of survival and disease-free interval in patients with dual primaries of breast and epithelial ovarian cancer versus patients with single primary epithelial ovarian cancer. *Gynecol Oncol* 2002;84:498

Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, Degeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2002;84:508-9

Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. *Proc ASCO* 2002;21:201a

Kudel I, Donnelly J, Cella D, McQuellon R, Zevon M, Moore D. Confirmatory factor analysis of the FACT-G: a GOG study. *Proc Society for Behavioral Med* 2003 (abstract)

Waggoner SE, Furham B, Darcy K, Parham G, Lucci J, Monk BJ, Moore DH. Influence of smoking on progression-free and overall survival in women with stage IIB, IIIB and IVA cervical carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2003;88:190

Fakiris AJ, Cardenes HR, Moore DH, Reddy SR, Look KY, Yiannoutsos CT, Randall ME. Intraperitoneal radioactive phosphorus (³²P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a Phase II Hoosier Oncology Group (97-01) study. *Gynecol Oncol* 2004;92:439

Harris SL, Randall ME, Look KY, Moore DH, Fakiris AJ, Lo S, Cardenes H. Outcome in surgically staged papillary serous and clear cell carcinoma of the uterus: a single institution experience (Abstract 5108). *Proc ASCO* 2005;23:481

Moore DH, Tian C, Monk BJ, Long HJ, Omura G. Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: a multivariate analysis of three Gynecologic Oncology Group trials (Abstract 5534). *Proc ASCO* 2007;25:282S

Institutional Committees

St. Francis Hospitals and Health Systems

Hospital

Cancer Care Committee 2006 – present

Institutional Review Board 2007 – present

Miscellaneous Educational and Professional Activities

Journal Reviewer

Cancer 2002-present

Gynecologic Oncology 1991-present
Editorial Board member 2000-2006
Editorial Board member 2008-present

International Journal of Gynecological Cancer 2002-present

Journal of Clinical Oncology 2004-present
Editorial Board member 2005-2008

Obstetrics and Gynecology 1987-present
Top 100 Reviewers 2003

Gynecologic Oncology Group

Principal Investigator
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
1990-1993

Co-Principal Investigator
Indiana University
Indianapolis, Indiana
1998-2006

Cervix and Vulva Committee
1993-present
Co-Chair, 1994-2001
Chair, 2002-2007

Committee of Experimental Medicine
1997-2003

Protocol Committee
1994-2006

Protocol Development Committee
2006-2007

Quality of Life Committee
1993-present

GOG Representative to ACRIN (American College of Radiology Imaging
Network)
1999-2002

Gynecologic Cancer Steering Committee
2006-present

Society of Gynecologic Investigation

Abstract Reviewer 2001 Annual Meeting

International Gynecologic Cancer Society

International Scientific Committee, 10th Biennial Meeting, 10/3-7/04, Edinburgh, Scotland

Society of Gynecologic Oncologists

Program Committee for the 1992 Annual Meeting

Staging and Nomenclature Committee 1993-1996

Program Committee for the 1995 Annual Meeting

Basic Science Award Committee 1995

Membership Committee 1999-2003

Clinical Practice Committee 2007-present
Chair, 2008-present

Nominating Committee 2007-present

SGO Council 2008 - present

Chairperson (with Gillian M. Thomas, MD and Robert F. Ozols, MD): Controversies in the Management of Gynecologic Malignancies II. December 13-14, 2001. The Grand Hyatt, New York, NY.

Chairperson (with Robert F. Ozols, MD): Controversies in the Management of Gynecologic Malignancies III. December 5-6, 2002. The Omni Shoreham Hotel, Washington, DC.

Chairperson (with Robert F. Ozols, MD): Controversies in the Management of Gynecologic Malignancies IV. December 13-14, 2003. Marriott Chicago Downtown, Chicago, IL.

Chairperson (with Robert F. Ozols, MD) Controversies in the Management of Gynecologic Malignancies V. December 3-4, 2004. The Grand Hyatt, New York, NY.

The American Cancer Society, North Carolina Division

Board of Directors 1989-1993

Special Projects Committee 1989-1993

Finance Committee 1989-1993

Orange County Unit Medical Advisor 1990-1991
President 1991-1993

North Carolina Medical Society

Young Physician's Delegate 1990 Annual Meeting
Pinehurst Hotel, Pinehurst, NC

American College of Obstetricians and Gynecologists

Junior Fellows Advisor
District IV, North Carolina Section 1991-1993

Program Chairman and Moderator
Indiana Section ACOG Meeting 4/21/99

Hoosier Oncology Group

Executive Committee 2000-present
HOG Golf Tournament Director 2000
HOG Golf Tournament Director 2003

Ovar'coming Together, Indianapolis, IN

Advisory Committee 2000-2002

Robert A. Ross Obstetrical and Gynecological Society

Chairman, Membership Committee 1989-1991

The Wellness Community, Indianapolis, IN

Professional Advisory Board 1996-present
Board of Trustees 2004-2010

Indiana State Medical Association

Convention Delegate 2008-2009

Extracurricular Activities

Indiana High School Academic All-Star Basketball Team 1974
Wabash College Varsity Basketball 1974-1975
Kentucky Derby Mini-Marathon 1980
Indianapolis '500' Mini-Marathon 1980-1981, 1983-1985
America's Marathon (Chicago) 1981, 1984
New York City Marathon 1985, 1987-1989
Pittsburgh Marathon 1989
Boston Marathon 1990-1991
Governor's Cup 25-Kilometer Race (Columbia, SC) 1989
Peachtree Road Race (Atlanta, GA) 1987, 1989
Capital Trail Run (Raleigh, NC) 1987-1988, 1990
UNC Hospitals Golf Tournament 1987-1993
James F. Newsome Memorial Golf Tournament 1988, 1990-1994

Orange County Invitational Golf Tournament 1988, 1990-1992
Bud Brexler Memorial Golf Tournament 1991 (won), 1992 (won)
Hoosier Oncology Group Golf Tournament 1993-5, 1997-2006
Indiana Amateur Golf Tournament Qualifying 1995, 1997-9
Indianapolis Amateur Golf Tournament 2001
Old Oakland Cup Golf Tournament 1997 (won)
Old Oakland Golf Club – Club Champion 2003
Old Oakland Golf Club – Senior Club Champion 2006, 2008
Hilly Hundred Bicycle Tour 1994, 2003, 2005, 2007, 2008

DHM 1/14/10